Table 1 Baseline characteristics of high risk NDMM patients.
From: VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma
Characteristics | VRd (n = 25) | VPd(n = 21) | p value |
|---|---|---|---|
Follow-up time, m(range) < 12 ≥ 12 | 18(72) 7(28) | 16(76.2) 5(23.8) | 0.747 |
Medina age, y(range) | 64(50–81) | 69(51–80) | 0.218 |
Male, n (%) | 10(40) | 12(57.1) | 0.245 |
Myeloma type, n (%) IgG/IgA Light chain only | 22(88) 3(12) | 20(95.2) 1(4.8) | 0.373 |
Creatinine Level, µmol/L(range) | 69(28–320) | 85(35–770) | 0.055 |
β2-MG, mg/L(range) | 7.15(3.03–14.39) | 7.59(5.50-71.62) | 0.109 |
DS I-II III | 2(8) 23(92) | 3(14.3) 18(85.7) | 0.496 |
ISS I-II III | 1(4) 24(96) | 0 21(100) | 0.266 |
R-ISS I-II III | 1(4) 24(96) | 1(4.8) 20(95.2) | 0.9 |
Chromosome Complex karyotype Normal | 4(16) 21(84) | 4 (19) 17(81) | 0.786 |
FISH Normal Abnormal | 1(4) 24(96) | 1(4.8) 20(95.2) | 0.9 |
EMD No Yes | 24(96) 1(4) | 19(90.5) 2(9.5) | 0.449 |
ASCT Yes No | 6(24) 19(76) | 1(4.8) 20(95.2) | 0.056 |
